Oncolys BioPharma Inc.

Research and development of pharmaceuticals and diagnostic agents requires long-term and substantial costs. If difficulties arise in concluding or maintaining license agreements, business revenue may decline, making reinvestment in new pipelines difficult. If the Company undertakes in-house development through to market launch, the substantial R&D expenses could pressure business performance and potentially lead to significant delays or discontinuation of development. The Company aims to minimize its own costs through the use of government subsidies and by transferring the burden of later-stage development costs to licensees, but the risk that plans do not proceed as intended remains.

If unexpected side effects or efficacy issues are discovered in pipelines under development, this could force significant delays or discontinuation of development, potentially having a material impact on the Company's business, financial condition, and operating results. The Company has implemented measures such as utilizing a scientific advisory board network, conducting safety verification at the non-clinical and preclinical stages, exchanging information with the PMDA and FDA, collaborating with CROs, establishing an SRB (Safety Review Board), and enrolling in clinical trial insurance, but it is difficult to completely eliminate the risk. For OBP-301, a marketing approval application was filed in December 2025 as a local therapeutic agent for esophageal cancer, and the outcome of the review will directly affect the business.

Pharmaceutical research and development requires compliance with guidelines under the Pharmaceuticals and Medical Devices Act, such as GLP, GMP, GCP, GQP, and GVP, and genetically modified viral products also require regulatory compliance under the Cartagena Act. If new laws or ordinances relating to pharmaceuticals or viral manufacturing are enacted or enforced in the future, this could constrain business activities and potentially lead to delays or discontinuation of development, or discontinuation of sales. The Company, as a manufacturer and marketer of regenerative medicine products, complies with relevant laws and regulations and has obtained the necessary administrative confirmations and approvals, but the risk of changes in the regulatory environment cannot be eliminated.

The Company's revenue structure is heavily dependent on upfront payments, milestone payments, and royalty income from license agreements. Changes in management strategy or portfolio reviews by licensee companies leading to discontinuation of development, or unexpected side effects occurring at licensees, would directly affect the Company's revenue. The Company currently has agreements with Transposon (OBP-601), Fujifilm Toyama Chemical (domestic sales of OBP-301), and Medigen (OBP-301 in Taiwan), but if these agreements are terminated or revised unfavorably and securing alternative partners is delayed, business performance would deteriorate. For pipelines not yet licensed out, there is no guarantee that they will meet the needs of prospective partner companies, and there is a risk that the timing and terms of agreements may differ from expectations.

In the oncolytic virus field, competing products exist such as T-VEC (Amgen), Delytact injection (Daiichi Sankyo), CG-0070 (Cold Genesys, Phase 3 for bladder cancer), and LOKON's product (Phase 2), and new entrants are increasingly entering this field. Although no similar competing products currently exist in the esophageal cancer field where the Company's OBP-301 is under marketing approval application, if oncolytic viruses or other pharmaceuticals enter this field in the future, this could affect pipeline-derived revenue. Additionally, in the drug discovery technology field overall, the pace of technological innovation is remarkably fast, and if competing technologies achieve significant advances, or if adopting such technologies requires substantial cost and time, this could affect the Company's business, financial condition, and operating results.

The Company bases its business on intellectual property rights, and if it becomes involved in conflicts with third-party patents or patent infringement lawsuits, resolving such matters could require substantial effort, time, and cost, potentially constraining business operations. The Company has secured patent rights and exclusive licenses domestically and internationally for its key pipelines (such as the patent for the endoscopic administration method of OBP-301 and the exclusive license for the stable formulation patent covering 24 countries obtained from ios Bio Ltd), but the risk that third-party patents other than the Company's own filed patents may be relevant cannot generally be eliminated. In addition, if disputes arise regarding compensation for employee inventions, this could also affect the financial position and operating results.

Most of the Company's outsourcing and partner companies/institutions are European and American entities, resulting in a large volume of foreign currency-denominated transactions, so fluctuations in exchange rates affect expenses and revenue after conversion into yen. While the Company's policy is to utilize hedging measures such as forward exchange contracts as necessary, it is difficult to avoid all risks, which could affect the business, financial condition, and operating results. In particular, a weaker yen could lead to increased R&D outsourcing costs.

The Company's research and development and business development strategy is heavily dependent on the experience and knowledge of President and Representative Director Yasuo Urata, gained through his career in the pharmaceutical industry, and there is a risk that business continuity could be hindered in his absence. While the Company is working to embed its corporate philosophy and management strategy throughout the organization and to develop successors, if organizational strengthening and business succession do not proceed smoothly, this could affect the Company's business, financial condition, and operating results.

The Company is a small organization, and with the transition toward a pharmaceutical company model, it is necessary to strengthen its regulatory affairs system and quality assurance operations; however, securing and developing project leaders, personnel with regulatory affairs experience, and personnel with quality assurance experience remains a challenge. If employees playing central roles leave the Company or if there are no substitute personnel available, this could affect the Company's business, financial condition, and operating results. The Company strives to improve retention rates through enhanced evaluation and personnel systems and by embedding its management philosophy, but competition for talent acquisition is intense.

The Company has implemented stock options, restricted stock, and issuances of new shares and share subscription rights for business promotion purposes, and may continue similar measures in the future, creating a risk of dilution in per-share value. Additionally, if the share price declines, the Company may be unable to raise necessary funds as planned, potentially forcing a change in the intended use of funds or a scaling back of R&D plans. The Company plans to allocate its funds to R&D expenses for existing and new pipelines and to strategic investments, but the risk remains that expected results may not be achieved due to sudden changes in the business environment.